Lidia La Barbera

Dr. Lidia La Barbera

Department of Promise, Università degli Studi di Palermo, Palermo, Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CRChiara Rizzo
Chiara Rizzo
Lidia La BarberaLidia La Barbera
Lidia La Barbera
MPMARIANNA LO PIZZO
MARIANNA LO PIZZO
FCFrancesco Ciccia
Francesco Ciccia
GSGuido Sireci
Guido Sireci
Giuliana GugginoGiuliana Guggino
Giuliana Guggino
Primary Sjogren syndrome (pSS) is a complex autoimmune disease mainly affecting salivary and lacrimal glands. Several factors contribute to pSS pathogenesis; in particular, innate immunity seems to play a key role in disease etiology. Invariant natural killer (NK) T cells (iNKT) are a T-cell subset able to recognize glycolipid antigens. Their function remains unclear, but studies have pointed out their ability to modulate the immune system through the promotion of specific cytokine milieu. In this review, we discussed the possible role of iNKT in pSS development, as well as their implications as future markers of disease activity.

Verified
Journal Article
Open access
PDF file
Lidia La BarberaLidia La Barbera
Lidia La Barbera
FMFederica Macaluso
Federica Macaluso
SFSerena Fasano
Serena Fasano
GGGiulia Grasso
Giulia Grasso
FCFrancesco Ciccia
Francesco Ciccia
Giuliana GugginoGiuliana Guggino
Giuliana Guggino
The microbial community acts as an active player in maintaining homeostasis and immune functions through a continuous and changeable cross-talk with the host immune system. Emerging evidence suggests that altered microbial composition, known as dysbiosis, might perturb the delicate balance between the microbiota and the immune system, triggering inflammation and potentially contributing to the pathogenesis and development of chronic inflammatory diseases. This review will summarize the current evidence about the microbiome-immunity cross-talk, especially focusing on the microbiota alterations described in patients with rheumatic diseases and on the recent findings concerning the interaction between microbiota, metabolic function, and the immune system.

4 February 2022 in Cells
Verified
Journal Article
Open access
PDF file
CRChiara Rizzo
Chiara Rizzo
FCFederica Camarda
Federica Camarda
DDDENISE DONZELLA
DENISE DONZELLA
Lidia La BarberaLidia La Barbera
Lidia La Barbera
Giuliana GugginoGiuliana Guggino
Giuliana Guggino
Spondyloarthritis (SpA) is a group of rheumatic diseases whose pathogenesis relies on a complex interplay between genetic and environmental factors. Over the last several years, the importance of the alteration of the gut microbiota, known as dysbiosis, and the interaction of bacterial products with host immunity have been highlighted as intriguing key players in SpA development. The recent advent of the so called “-omics” sciences, that include metabolomics, opened the way to a new approach to SpA through a deeper characterisation of the pathogenetic mechanisms behind the disease. In addition, metabolomics can reveal potential new biomarkers to diagnose and monitor SpA patients. The aim of this review is to highlight the most recent advances concerning the application of metabolomics to SpA, in particular focusing attention on Ankylosing Spondylitis and Psoriatic Arthritis.

1 February 2024 in Cells
Verified
Journal Article
Open access
PDF file
Lidia La BarberaLidia La Barbera
Lidia La Barbera
CRChiara Rizzo
Chiara Rizzo
FCFederica Camarda
Federica Camarda
GMGiuseppe Miceli
Giuseppe Miceli
Antonino TuttolomondoAntonino Tuttolomondo
Antonino Tuttolomondo
Giuliana GugginoGiuliana Guggino
Giuliana Guggino
Large-vessel vasculitis (LVV) are autoimmune and autoinflammatory diseases focused on vascular inflammation. The central core of the intricate immunological and molecular network resides in the disruption of the “privileged immune state” of the arterial wall. The outbreak, initially primed by dendritic cells (DC), is then continuously powered in a feed-forward loop by the intimate cooperation between innate and adaptive immunity. If the role of adaptive immunity has been largely elucidated, knowledge of the critical function of innate immunity in LVV is still fragile. A growing body of evidence has strengthened the active role of innate immunity players and their key signaling pathways in orchestrating the complex pathomechanisms underlying LVV. Besides DC, macrophages are crucial culprits in LVV development and participate across all phases of vascular inflammation, culminating in vessel wall remodeling. In recent years, the variety of potential pathogenic actors has expanded to include neutrophils, mast cells, and soluble mediators, including the complement system. Interestingly, new insights have recently linked the inflammasome to vascular inflammation, paving the way for its potential pathogenic role in LVV. Overall, these observations encourage a new conceptual approach that includes a more in-depth study of innate immunity pathways in LVV to guide future targeted therapies.


13 January 2025 in Reumatismo
Verified
Journal Article
Open access
PDF file
CRChiara Rizzo
Chiara Rizzo
SGSilvia Grazzini
Silvia Grazzini
ECEdoardo Conticini
Edoardo Conticini
HCHector Chinoy
Hector Chinoy
RDRoberto D’aLessandro
Roberto D’aLessandro
Lidia La BarberaLidia La Barbera
Lidia La Barbera
Objective. Idiopathic inflammatory myopathies (IIM) are rare autoimmune diseases that primarily affect striated muscles; skin, joints, and lungs may be involved with different degrees of severity. Traditional treatment relies on high-dose glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs. Methods. A growing amount of evidence is demonstrating the potential role of novel treatments in the management of IIM. We report our experience with Janus kinase inhibitors (JAKi) in these conditions and review the current evidence for the use of small molecules in real-life clinical practice. Results. A total of 41 papers were retrieved from PubMed, 37 papers concerning IIM and JAKi, and 4 papers concerning IIM and apremilast. Conclusions. An overall good efficacy was evidenced in IIM-associated skin lesions, including rash, ulcers, and calcinosis. If present, muscle and joint involvement demonstrated a good response to therapy, while it was not possible to draw any conclusion about dysphagia. No life-threatening adverse events were reported.